Helicon group has signed a cooperation agreement with Jewim Pharmaceuticals, a leading player in the Chinese pharmaceutical industry.
The deal, signed with Beijing based Jewim Pharmaceuticals., is designed to draw on the strengths of each party in successfully bringing new biomedical technologies to the China market.
Representing such majors as Novartis, Astra Zeneca and Wyeth, Jewim is the largest distributor of pharmaceuticals and devices to Chinese oncology units with for example 100% coverage to the hospitals with Oncology units in the larger cities of Shanghai, Beijing and Guangzhou.
Helicon has identified the Chinese oncology segment as one of its target markets and is actively seeking oncology related technologies to add to its portfolio "We are very pleased to establish this relationship with the Helicon Group. This relationship will provide Jewim with access to ongoing stream of Western medical technologies for commercialization in China" said Dr. Song Gengfu, President of Jewim Pharmaceuticals Inc at the formal signing ceremony in Beijing.
"This alliance with Jewim Pharmaceuticals is yet another step in Helicon's strategy to build its capability with alliances with established partners in the specialist areas such as the highly lucrative oncology market in China. Jewim will provide Helicon with the necessary leverage to gain rapid market penetration with its extensive distribution and marketing capability." said Peter Abrahamson, Helicon's CEO.